Clinical Data Novo, Lilly trade oral GLP-1 data readouts at ECO PharmaphorumNovo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables.Metabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 16, 2026) Pharmaphorum Novo Nordisk trumpets oral Wegovy efficacy data at ECO, while Lilly builds the case for switching to Foundayo in maintenance phase after injectables. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Isomorphic Labs receives $2.1bn for AI drug developmentNext: UAE approves AstraZeneca’s Baxfendy for hypertension Related Stories Clinical Data ECO 2026: tirzepatide shows potential for T1D treatment pharminent May 15, 2026 Clinical Data Biogen’s Alzheimer’s results bolster tau theory–and Denali’s next gen candidate pharminent May 15, 2026 Clinical Data Regenxbio’s Duchenne gene therapy clears phase 3 hurdle pharminent May 14, 2026
